The importance of new companies for drug discovery: origins of a decade of new drugs

Robert Kneller

In figure 7, the second column in panels a and b should have been labelled 'NDA/BLA applicant'. In the legend for figure 7, and in the article text related to this figure on p879, the subset of the drugs analysed in panel a are those with peak year sales above US$500 million, rather than mean peak year sales.